@article{JTD28068,
author = {Jeronimo Rafael Rodríguez-Cid and Orlando García-Acevedo and Javier Benjamin-Contreras and Diana Bonilla-Molina and Rodrigo Rafael Flores-Mariñelarena and Luis Martínez-Barrera and Jorge Arturo Alatorre-Alexander and Carla Paola Sanchez-Ríos and Maria del Rosario Flores-Soto and Patricio Javier Santillan-Doherty and Erika Sagrario Peña-Mirabal},
title = {Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective estrogen receptor beta (ERβ) agonists increases the susceptibility to antitumor treatment.
Methods: This was a retrospective single center study that analyzed the response of malignant pleural mesothelioma with an expression of ERβ to first-line chemotherapy. The study included patients with pleural mesothelioma pathologically confirmed between 2013 and 2016 at the National Institute for Respiratory Disease (INER), who underwent an immunohistochemistry assay for ERβ (mouse monoclonal antibody PPG5/10). The primary endpoint was the response to chemotherapy based on RECIST 1.1 according to the ERβ expression; secondary outcomes were the overall survival (OS) and progression-free survival (PFS).
Results: We included 22 patients, regarding the expression of ERβ, 17 (77.2%) patients had high or moderate degree, while 5 (22.7%) had low degree or null expression. The response to treatment as by RECIST 1.1, 12 (54.5%) had partial response, 5 (22.7%) had stable disease, and 3 (13.6%) had progression. None of the patients had a complete response. Of those who had a partial response, 9 (75%) had a high or moderate degree of ERβ expression in tumor cells, and 3 (25%) had a low or null degree of expression.
Conclusions: High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/28068}
}